Organogenesis Holdings (ORGO) Income from Continuing Operations (2016 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Income from Continuing Operations of 53156000.0 for Q1 2026, down 182.1% year-over-year from 64745863.48 in Q1 2025, and down 208.25% quarter-over-quarter from 49105000.0 in Q4 2025.
Organogenesis Holdings (ORGO) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 53156000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 182.1% year-over-year to 53156000.0; the TTM figure through Mar 2026 stood at 8124000.0 (up 151.15% YoY), while the FY2025 annual figure was 42437000.0, up 4828.8% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 53156000.0, down from 49105000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 49105000.0 in Q4 2025, with the low at 53156000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 1444000.0 (2023), against an average of 743058.82.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations jumped 1373.02% in 2023, then tumbled 797.29% in 2025.
- Organogenesis Holdings' Income from Continuing Operations stood at 7486000.0 in 2022, then slumped by 80.71% to 1444000.0 in 2023, then soared by 431.37% to 7673000.0 in 2024, then jumped by 539.97% to 49105000.0 in 2025, then tumbled by 208.25% to 53156000.0 in 2026.
- Business Quant data shows ORGO's Income from Continuing Operations at 53156000.0 in Q1 2026, 49105000.0 in Q4 2025, and 21567000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 242.55 Mn | 195.71 Mn | 20.08 Mn | -96.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.27 Mn |
| Mar 31, 2026 | -53.16 Mn |
| Dec 31, 2025 | 49.11 Mn |
| Sep 30, 2025 | 21.57 Mn |
| Jun 30, 2025 | -9.39 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | 7.67 Mn |
| Sep 30, 2024 | 12.33 Mn |
| Jun 30, 2024 | -17.04 Mn |
| Mar 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | -2.97 Mn |
| Dec 31, 2022 | 7.49 Mn |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 8.74 Mn |
| Mar 31, 2022 | -913,000.00 |
| Dec 31, 2021 | 19.02 Mn |
| Sep 30, 2021 | 12.58 Mn |